Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Modalis Therapeutics Corporation (4883.T)
Tokyo, JP
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.47% | +6.35% | +24.07% | +17.54% | -4.29% | +15.52% | -9.46% | -72.87% | -95.44% | -97.00% | -97.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+2.5% Q1'26: +59.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +10,975.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+67.5% Q1'26: +22.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
342.00M
est: 341.33M (+0.2%)
|
1.10M
est: 1.60B (-99.9%)
|
40.50M
est: 840.50M (-95.2%)
|
—
est: 650.00M (-100.0%)
|
—
est: 1.65B (-100.0%)
|
—
est: 2.05B (-100.0%)
|
800.00M
800.00M – 800.00M
-61.0% YoY
|
| EBITDA |
-381.96M
est: -68.27M (-459.5%)
|
-667.55M
est: -320.67M (-108.2%)
|
-2.58B
est: -168.10M (-1,436.8%)
|
-2.37B
est: -130.00M (-1,726.1%)
|
-2.15B
est: 330.00M (-750.6%)
|
-2.21B
est: 410.00M (-639.5%)
|
160.00M
160.00M – 160.00M
-61.0% YoY
|
| EBIT |
-439.55M
est: -68.27M (-543.9%)
|
-744.33M
est: -320.67M (-132.1%)
|
-2.71B
est: -168.10M (-1,510.4%)
|
-2.37B
est: -130.00M (-1,726.7%)
|
-2.15B
est: 330.00M (-750.8%)
|
-2.21B
est: 410.00M (-639.5%)
|
160.00M
160.00M – 160.00M
-61.0% YoY
|
| Net Income |
-448.41M
est: -402.84M (-11.3%)
|
-738.96M
est: 903.17M (-181.8%)
|
-2.70B
est: -1.51B (-79.3%)
|
-2.39B
est: -1.95B (-22.4%)
|
-1.32B
est: -1.08B (-22.3%)
|
-2.15B
est: -219.45M (-880.9%)
|
-1.72B
-1.72B – -1.72B
-681.7% YoY
|
| SGA |
208.45M
est: 14.92B (-98.6%)
|
231.02M
est: 70.10B (-99.7%)
|
241.99M
est: 36.75B (-99.3%)
|
267.81M
est: 28.42B (-99.1%)
|
220.00M
est: 72.27B (-99.7%)
|
231.81M
est: 89.79B (-99.7%)
|
35.04B
35.04B – 35.04B
-61.0% YoY
|
| EPS |
-17.02
est: -8.73 (-94.9%)
|
-25.70
est: 19.58 (-231.3%)
|
-92.85
est: -32.68 (-184.1%)
|
-77.24
est: -42.37 (-82.3%)
|
-28.57
est: -13.94 (-104.9%)
|
-27.86
est: -2.84 (-881.0%)
|
-22.20
-22.20 – -22.20
-681.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haruhiko Morita | Co-Founder, Chairman, President & Chief Executive Officer | — | male |
| Tetsuya Yamagata | Chief Scientific Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4883.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
